Agilent Technologies, Inc.
AHealthcareNASDAQDiagnostics & Research · Last scanned Jun 3, 2026
Scan Results
Daily timeframeAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. At a $38.14B market cap, Agilent Technologies, Inc. ranks as a large-cap company within healthcare. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Market Cap
$38.14B
Beta
1.22
P/E (TTM)
27.12
P/E (Fwd)
20.46
EPS (TTM)
$4.98
EPS (Fwd)
$6.60
ROE
21.3%
ROA
8.6%
Cash
$1.81B
Total Debt
$3.36B
Free CF
$933.4M
52W Change
17.5%
Annual Financials
Cash vs Debt
The company holds $1.81B in cash, though total debt stands at $3.36B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $933.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 21.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.85B (2022) to $6.95B (2025).
Investors considering Agilent Technologies, Inc. should weigh the typical risks associated with A's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Agilent Technologies, Inc. and its sector.